In the current study, IHC revealed 13 of 857 (1.5%) consecutive ESCC cases to have a status of HER2 overexpression (3+) and 52 of 857 (6.1%) to have a status of HER2 equivocal expression (2+). The gene discussed is ERBB2; the disease is esophageal squamous cell carcinoma.